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Does a History of Eczema Predict
a Future Basal Cell Carcinoma?
Christina A. Gamba1 and Jean Y. Tang2
Dyer et al. (this issue) assess the risk of new basal cell carcinoma (BCC) in the
Veterans Affairs topical tretinoin chemoprevention trial, which included indivi-
duals with a history of at least two prior keratinocyte carcinomas. In addition to
known risk factors for a future BCC, such as number of prior BCCs, a history of
eczema and lower education levels were also associated with greater risk.
Journal of Investigative Dermatology (2012) 132, 2497–2499; doi:10.1038/jid.2012.323
Introduction
Among individuals with a primary basal
cell carcinoma (BCC), 44% will develop a
subsequent BCC within 3 years, a 10-fold
higher incidence than the general popula-
tion (Marcil and Stern, 2000). Dyer et al.
(2012, this issue) again illustrate the high
rate of BCC development in individuals at
high risk for skin cancer, particularly those
with a prior history of keratinocyte carci-
noma (KC; e.g., BCC or squamous cell
carcinoma (SCC)). Because BCCs are so
common, their treatment is a consi-
derable health-care burden, especially in
Medicare and Veterans Affairs (VA) popu-
lations. Therefore, identifying modifiable
risk factors for new BCC in high-risk, non-
immunosuppressed patients is a priority.
Dyer et al. (2012) present data on risk
factors for BCC on the face or ears in
1131 VA patients with at least two prior
KCs, who were enrolled in the VA topical
tretinoin chemoprevention (VATTC)
trial and followed up for a median of
3.6 years.
Previously identified risk factors for
future BCC
Several studies have evaluated risk fac-
tors for the development of subsequent
BCCs after primary BCC or SCC, exclud-
ing BCC recurrence (Marcil and Stern,
2000; Karagas et al., 1992). The only
consistent risk factor for subsequent BCC
in a meta-analysis was the number of
previous skin cancers, whereas conflict-
ing results were found for age and sex
(Marcil and Stern, 2000). Other studies
have found an association with skin type,
solar skin damage, and recreational sun
exposure (Karagas et al., 1992). As with
the aforementioned studies, the number
of prior BCCs was the most significant
risk factor for the development of new
BCCs on the face or ears in VATTC parti-
cipants (hazard rate ratio (HRR) 4.01;
95% confidence interval (CI): 3.02–
5.31), but several other unique risk
factors, such as history of eczema and
lower education level, were also
identified in this largely older
Caucasian male VA population.
History of eczema
Dyer et al. (2012) report that the 52
VATTC participants with a history of
eczema had a 54% higher risk of deve-
loping new BCC on the face and ears
(multivariate HRR 1.54; 95% CI 1.03–
2.32). History of eczema was based
on subjects’ self-report of ever being told
by a doctor that they had eczema, without
further information on timing, duration, or
severity of eczema. Several studies have
evaluated the association between atopic
dermatitis or eczema and non-melanoma
skin cancer (NMSC), with inconsistent
results (Arana et al., 2010; Tennis et al.,
2011; Jensen et al., 2012), but the data
presented by Dyer et al. (2012) are the
first to consider the history of eczema in
a high-risk population.
A review by Tennis et al. (2011) high-
lighted the inconsistent findings on
eczema and NMSC, noting that two
clinic-based, case–control studies repor-
ted a protective relationship between
eczema and NMSC, whereas two hos-
pital-based cohort studies reported a
greater risk of NMSC among patients
discharged with an eczema diagnosis.
Since this review, two additional cohort
studies have found a 1.4-fold higher risk
of NMSC in individuals with a diagnosis
of eczema. The first, a retrospective
cohort study in The Health Improvement
Network, representative of the general
UK population, found that individuals
with eczema had a 46% greater risk of
NMSC (e.g., BCC and SCC combined),
but the analysis only adjusted for sex
and age, as skin cancer risk factors and
history of eczema treatments were
unavailable (incidence rate ratio 1.46;
95% CI 1.27–1.69; Arana et al., 2010).
Similarly, in a Danish hospital-based
cohort study, patients with a diagnosis
of eczema and asthma had a 41% higher
risk of BCC (standardized incidence ratio
(SIR) 1.41; 95% CI 1.07–1.83), but
diagnosis of eczema alone was not
associated significantly with BCC (SIR
1.29; 95% CI 0.92–1.77; Jensen et al.,
2012). Comparing the studies of eczema
and NMSC is challenging, as determi-
nation of eczema status varied greatly in
each (from mailed-surveys to discharge
diagnoses codes), and adjustment for
skin cancer risk factors was limited. In
addition, few of these studies assessed
eczema severity, duration, and timing in
relation to the development of NMSC.
It is uncertain whether the association
of eczema with BCC is causal. Eczema
could increase BCC risk secondary to
chronic inflammation or to the possible
use of carcinogenic or immunosuppres-
sive treatments for patients with severe
disease (Arana et al., 2010; Jensen et al.,
2012). Eczema could also be associated
with a BCC diagnosis owing to increa-
sed dermatologic surveillance and thus
greater BCC detection. Atopic conditions,
such as eczema, have been linked to
cancer by two opposing hypotheses: one,
that immunity is hyper-reactive and thus
inhibits cancer development; or two,
that the chronic inflammation induces
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mutagenesis and thus increases cancer
risk (Arana et al., 2010). Classically,
eczema involves the flexural surfaces of
extremities, so the greater risk of BCC in
VATTC participants was in areas gene-
rally unaffected by adult forms of atopic
eczema (e.g., face or ears), thus seemin-
gly reducing the likelihood that chronic
inflammation may have predisposed
these patients to skin cancer.
Others cite the carcinogenic potential
of certain eczema treatments, such as
topical calcineurin inhibitors. These
agents have carried a ‘‘black box’’ warn-
ing since 2006, owing to concern that
they may be associated with a higher risk
of skin cancer and lymphoma (both cuta-
neous and non-cutaneous), based on
results from animal models and case
reports (Tennis et al., 2011). However,
epidemiological studies have not suppor-
ted a link between topical calcineurin
inhibitors and skin cancer (Tennis et al.,
2011). Notably, none of the VATTC parti-
cipants with eczema had used topical
calcineurin inhibitors. Other treatments
for severe eczema that have been cited
for their immunosuppressive or carcino-
genic potential include oral calcineurin
inhibitors, azathioprine, oral glucocorti-
coids, and UV phototherapy (Jensen
et al., 2012), but these were not evalu-
ated in the VATTC participants.
Increased surveillance may explain
the higher incidence of BCC in some
patients with eczema, as they may be
more likely to have skin examinations
compared with the general population.
However, this does not account for
the higher risk of new BCC in VATTC
participants with a history of eczema,
as all individuals in the trial underwent
regular skin examinations. Thus, the
results by Dyer et al. (2012) may be
explained either by a chance finding in
a small population (n¼52) or because
either eczema or its treatment may lead
to a higher risk of BCC in areas other-
wise unaffected by eczema (e.g., the
face or ears).
Education
In VATTC participants, higher education
(e.g., some college versus no college)
was protective against new BCCs. Com-
monly, in low-risk, general populations,
higher education is associated with
higher risk of BCC, probably secondary
to the patterns of sun exposure seen in
high socioeconomic groups (e.g., high,
intermittent sun exposure during out-
door activities or on vacations; Steding-
Jessen et al., 2010). Americans from low
socioeconomic groups, either based on
education or income, are less likely to
have skin examinations (Saraiya et al.,
2004) and to use sunscreens (Buller
et al., 2011). In this high-risk popula-
tion, patients with higher education may
have practiced more sun-protective
behaviors such as sun avoidance and
sunscreen use.
Sun exposure and sunscreen use
Dyer et al. (2012) also report that occu-
pational sun exposure before the age
of 30 years was associated with higher
risk of new BCC of the face or ears, con-
sistent with a meta-analysis that found a
40% higher risk of BCC with occupa-
tional UV exposure (Bauer et al., 2011).
Other sun exposure variables were not
associated with BCC risk, including
occupational sun exposure after the
age of 30 years, recreational time spent
outside, sunburns, and latitude of resi-
dence. Dyer et al. (2012) also report that
SPF15þ use in the last week was asso-
ciated with a higher risk of new BCC
(HRR 1.25, 95% CI 1.01–1.54), whereas
there was no association with SPF15þ
use in the last 6 months or with any
sunscreen use (regardless of SPF; Dyer
et al., 2012). Sunscreen use and higher
SPF have been associated with greater
duration of sun exposure and higher
numbers of sunburns (Autier et al.,
2007). Thus, the individuals using
SPF15þ in the last week may have
been at higher risk for BCC, but the
findings by Dyer et al. (2012) on sun-
screen use also highlight that sun-pro-
tective behaviors in individuals with a
history of skin cancer may be insuffi-
cient to prevent new BCCs.
Conclusion
The report by Dyer et al. (2012) not
only confirms that prior BCCs are an
important predictor of future BCCs, but
also highlights the need for further
research on risk factors for new BCCs
in high-risk, non-immunosuppressed
populations. Prior studies in the
general population have suggested that
eczema is associated with greater risk of
NMSC. Similarly, Dyer et al. (2012)
found that history of eczema (n¼52),
in the absence of topical calcineurin
inhibitor use, was a risk factor for new
BCCs of the face and ears in high-risk
individuals. Interestingly, the new BCCs
were in areas not classically affected by
eczema. It is unclear whether the asso-
ciation between eczema and NMSC is
secondary to the chronic inflammatory
disease state or to the treatments for
severe eczema that may be carcino-
genic or immunosuppressive. Notably,
greater skin surveillance in patients with
eczema is unlikely to explain the higher
risk of BCC in the VATTC participants,
as skin examinations were performed
routinely as part of the trial. This report
adds further credence to epidemio-
logical studies that have found no
association between topical calcineurin
inhibitors and NMSC by highlighting
the issue of confounding by indication,
whereas topical calcineurin inhibitors
may be associated with NMSC if used
to treat eczema, which is independently
associated with NMSC. Relevant areas
for future research include analysis of
eczema severity, duration, timing, and
treatment in relation to the development
of NMSC, as well as further studies of a
potential biological mechanism.
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Clinical Implications
 History of eczema, in the absence of topical calcineurin inhibitor use,
may be an independent risk factor for basal cell carcinoma (BCC) of
the face and ears.
 Early-life sunlight exposure is a risk factor for BCC.
Men with higher education have a lower risk of future BCCs.
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Endemic Pemphigus Foliaceus:
Towards Understanding Autoimmune
Mechanisms of Disease Development
Giovanni Di Zenzo1, Giovanna Zambruno1 and Luca Borradori2
Fogo selvagem is an endemic form of pemphigus foliaceus (EPF) found in Brazil.
Environmental and genetic factors are thought to contribute to the disease, which
is associated with pathogenic IgG4 autoantibodies against the desmosomal
cadherin desmoglein 1. In this issue, as an additional framework to understand
autoimmune mechanisms in EPF, Flores et al. have investigated whether fogo
selvagem patients and healthy individuals from endemic areas develop autoanti-
body responses against other desmosomal cadherins and E-cadherin.
Journal of Investigative Dermatology (2012) 132, 2499–2502; doi:10.1038/jid.2012.369
Pemphigus comprises a group of poten-
tial life-threatening autoimmune blister-
ing diseases of the skin and mucous
membranes. This group of diseases is
characterized by autoimmune responses
directed specifically against two trans-
membrane components of desmosomes,
desmoglein (Dsg) 3 and Dsg1, adhesion
molecules of the cadherin family. Addi-
tional targeted antigens have been
identified recently, the pathogenic signi-
ficance of which has not been demon-
strated conclusively. The two major
forms of the disease—pemphigus vul-
garis (PV) and pemphigus foliaceus
(PF)—differ clinically. PF develops as
either sporadic disease occurring all over
the world or in an endemic form. The
latter is found mainly in certain areas of
Brazil, where the disease is known as
fogo selvagem (wildfire), as well as in
other South and Central American coun-
tries (Diaz et al., 1989; Abre`u-Velez
et al., 2003). Finally, an endemic form
of PF has been also described in North
Africa (Kallel Sellami et al., 2004).
Although endemic PF (EPF) and the
sporadic form share similar clinicopatho-
logical features and the presence of patho-
genic IgG anti-Dsg1 antibodies, fogo
selvagem has peculiar characteristics.
Fogo selvagem and its unique
epidemiology
Over the past 25 years, Diaz and the
Cooperative Group on Fogo Selvagem
Research have carried out a series of
remarkable epidemiologic and immuno-
logic studies on a specific population of
Amerindians living in the Terena reser-
vation of Limao Verde in Mato Grosso
do Sul, Brazil. In this population, the
prevalence of EPF is approximately
3.5%. Most of the affected patients are
children and young adults, who often
work outdoors and live in forested areas
near rivers and streams, in poor hygienic
and housing conditions. A strong rela-
tionship has been found between the
occurrence of fogo selvagem and
infestation with hematophagous insects
such as Simulium (also called black
fly; Aoki et al., 2004). Strikingly, up to
80% of subjects living in these areas
who suffer from hematophagous vector-
borne parasitic diseases such as
onchocerciasis, leishmaniasis, and
Chagas disease also exhibit anti-Dsg1
antibodies (Diaz et al., 2004). Patients
with fogo selvagem show circulating
IgM and IgE anti-Dsg1 antibodies,
which have been thought to result
from continuous antigenic stimulation
(Qian et al., 2011). Together, these obser-
vations have supported the idea that
environmental factors have a key role in
triggering EPF in individuals with certain
HLA susceptibility genes, especially
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